AbbVie, Voyager to develop single gene therapy for Alzheimer’s – PharmaTimes
PharmaTimes |
AbbVie, Voyager to develop single gene therapy for Alzheimer's
PharmaTimes The collaboration aims to develop a potential one-time treatment using Voyager's gene therapy platform to reduce tau pathology through the delivery of an AAV vector antibody that encodes the genetic instructions to produce anti-tau antibodies within … AbbVie, Voyager Collaborate for Vectorized AD Antibodies |
